Medicine Press release

Eisai Co., Ltd. and Biogen Inc. announced today that humanized anti- soluble aggregated amyloid-beta (Aβ) monoclonal antibody "LEQEMBI(R)" (generic name: lecanemab) has been approved for once every four weeks intravenous (IV) maintenance dosing by the Medicines and Healthcare products Regulatory Agency (MHRA) in the United Kingdom.
More info..

Eisai Co., Ltd. and Biogen Inc. announced today that humanized anti- soluble aggregated amyloid-beta (Aβ) monoclonal antibody "LEQEMBI(R)" (generic name: lecanemab) has been approved for once every four weeks intravenous (IV) maintenance dosing by the Medicines and Healthcare products Regulatory Agency (MHRA) in the United Kingdom.
More info..

The Japan Foundation of Cancer Research (JFCR) and NEC Corporation (NEC; TSE: 6701) have confirmed research results supporting the development of a novel personalized neoantigen cancer vaccine using whole-genome data (*1).
More info..

The Japan Foundation of Cancer Research (JFCR) and NEC Corporation (NEC; TSE: 6701) have confirmed research results supporting the development of a novel personalized neoantigen cancer vaccine using whole-genome data (*1).
More info..

The Japan Foundation of Cancer Research (JFCR) and NEC Corporation (NEC; TSE: 6701) have confirmed research results supporting the development of a novel personalized neoantigen cancer vaccine using whole-genome data (*1).
More info..

Olympus Corporation (Olympus), a global MedTech leader dedicated to making people's lives healthier, safer, and more fulfilling, today unveiled a comprehensive strategy to transform endoscopy-enabled care through innovation and operational excellence.
More info..

Olympus Corporation (Olympus), a global MedTech leader dedicated to making people's lives healthier, safer, and more fulfilling, today unveiled a comprehensive strategy to transform endoscopy-enabled care through innovation and operational excellence.
More info..

HighTide Therapeutics, Inc. (2511.HK), a biopharmaceutical company specializing in the development of multifunctional, multi-targeted therapies for chronic metabolic diseases, announced positive 52-week safety and efficacy results from the open-label extension (OLE) phases of two Phase III trials (SYMPHONY-1 and SYMPHONY-2) evaluating HTD1801 in patients with type 2 diabetes mellitus (T2DM).
More info..

HighTide Therapeutics, Inc. (2511.HK), a biopharmaceutical company specializing in the development of multifunctional, multi-targeted therapies for chronic metabolic diseases, announced positive 52-week safety and efficacy results from the open-label extension (OLE) phases of two Phase III trials (SYMPHONY-1 and SYMPHONY-2) evaluating HTD1801 in patients with type 2 diabetes mellitus (T2DM).
More info..

HighTide Therapeutics, Inc. (2511.HK), a biopharmaceutical company specializing in the development of multifunctional, multi-targeted therapies for chronic metabolic diseases, announced positive 52-week safety and efficacy results from the open-label extension (OLE) phases of two Phase III trials (SYMPHONY-1 and SYMPHONY-2) evaluating HTD1801 in patients with type 2 diabetes mellitus (T2DM).
More info..